Inactive Instrument

Press Releases StemCells Inc Nasdaq

Equities

US85857R2040

End-of-day quote Nasdaq Other stock markets
- ^USD	-

Apr. 29	Microbot Medical Announces Positive Results from the First Phase of Its Collaboration with Corewell Health	CI
Apr. 16	HC Wainwright Adjusts Microbot Medical's Price Target to $7 From $8, Keeps Buy Rating	MT

Press Releases

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Microbot Medical Announces Positive Results from the First Phase of its Collaboration with Corewell Health™	Apr. 29	GL
Microbot Medical Shares Status Following Recent Geopolitical Events	Apr. 15	GL
Microbot Medical Submits an IDE Application to Gain FDA Approval to Commence Its Pivotal Clinical Trial in the US	Feb. 05	GL
Microbot Medical Announces Settlement and Release Agreement, Effectively Resolving all Associated Legal Matters	Jan. 30	GL
Microbot Medical Expands US Clinical Infrastructure in Support of the Upcoming IDE Submission to Commence its First in Human Clinical Study	Jan. 18	GL
Microbot Medical Expands US Clinical Infrastructure in Support of the Upcoming IDE Submission to Commence its First in Human Clinical Study	Jan. 18	AQ
Microbot Medical Announces Exercise of Outstanding Preferred Investment Options for $2.73 Million in Gross Proceeds Priced At-the-Market Under Nasdaq Rules	Dec. 29	GL
Microbot Medical Announced Positive Results of Its GLP Pivotal Pre-Clinical Study Where All Study Objectives Were Met	Dec. 28	GL
Microbot Medical Announced Positive Results of Its GLP Pivotal Pre-Clinical Study Where All Study Objectives Were Met	Dec. 28	AQ
Microbot Medical and Corewell Health Forge Collaboration to Establish the LIBERTY® Endovascular Robotic Surgical System for Telerobotic	Dec. 14	GL
Microbot Medical Announces the Successful Completion of Its GLP Pivotal Pre-Clinical Study, a Critical Milestone for Its IDE submission to Commence Human Clinical Study	Dec. 07	GL
Microbot Medical Announces the Successful Completion of Its GLP Pivotal Pre-Clinical Study, a Critical Milestone for Its IDE submission to Commence Human Clinical Study	Dec. 07	AQ
Microbot Medical : Material Event - Form 8-K	Dec. 01	PU
Microbot Medical Appoints Seasoned Medical Expert Dr. Juan Diaz- Cartelle as its New Chief Medical Officer in Anticipation of Its Clinical, Regulatory and Commercial Activities	Nov. 21	GL
Microbot Medical Successfully Completed Integral Part of the Verification and Validation Process	Nov. 13	GL
Microbot Medical Granted Registered Trademark from The U.S. Patent and Trademark Office	Nov. 08	GL
Microbot Medical Granted Registered Trademark from The U.S. Patent and Trademark Office	Nov. 08	AQ
Microbot Medical : Granted Registered Trademark from The U.S. Patent and Trademark Office - Form 8-K	Nov. 08	PU
Microbot Medical Reveals Successful Short Term Follow Up Outcomes from its Pivotal Pre-Clinical Study	23-10-31	GL
Microbot Medical Reveals Successful Short Term Follow Up Outcomes from its Pivotal Pre-Clinical Study	23-10-31	AQ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases StemCells Inc Nasdaq

Equities

US85857R2040

Press Releases

Filters